Intervention

Esketamine

ClinicalTrials.gov intervention label

Clinical trials20

Recruiting5

Common conditions21

Lead sponsors shown14

Clinical trials

20 shown

A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive DisorderNCT07227454 · 2026-01-08

Metabolic Profiling of Esketamine Treatment in Depressive DisorderNCT07002684 · 2023-04-01

Long-Term Maintenance With Ketamine and Esketamine for Reduction of Suicide in High-Risk Patients With DepressionNCT05450432 · 2022-10-13

University of Iowa Interventional Psychiatry Service Patient RegistryNCT04480918 · 2020-11-02

Effects of an Opioid Free/Sparing Care Pathway for Patients Undergoing Obesity SurgeryNCT03756961 · 2019-05-01

Behavioural Activation Therapy and Esketamine for Resistant DepressionNCT06431386 · 2024-06-11

VA Aripiprazole vs Esketamine for Treatment Resistant DepressionNCT05554627 · 2023-10-27

Dexmedetomidine-esketamine Combined Nasal Administration and Perioperative Sleep QualityNCT05732064 · 2023-05-22

Ayahuasca and Esketamine for Major DepressionNCT07212946 · 2022-10-30

Effect of Esketamine on Postoperative Depression、Gut Microbiota、Bispectral Index Data of Depression Patients Undergoing Breast Cancer Operation (ESPOD-BI)NCT04303325 · 2021-10-08

A Long-Term Extension Study for Participants With Treatment-resistant Major Depressive Disorder Who Are Continuing Esketamine Nasal Spray TreatmentNCT04829318 · 2021-04-26

Esketamine and Perioperative Depressive SymptomsNCT04425473 · 2021-02-19

Effect of Low-dose Esketamine on Postoperative Depression in Patients With Breast CancerNCT04850937 · 2021-02-10

Imaging Neural Correlates of Ketamine Using PET/MRNCT04587778 · 2020-10-05

Study to Evaluate the Efficacy and Safety of 3 Fixed Doses of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Pediatric Participants Assessed to be at Imminent Risk for SuicideNCT03185819 · 2017-10-05

54135419SUI3002: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Adult Participants Assessed to be at Imminent Risk for SuicideNCT03097133 · 2017-06-15

54135419SUI3001: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Adult Participants Assessed to be at Imminent Risk for SuicideNCT03039192 · 2017-06-09

A Study to Evaluate the Effects of a Single-Dose and Repeat-Administration of Intranasal Esketamine on On-Road Driving in Participants With Major Depressive DisorderNCT02919579 · 2016-10-07

A Double-blind Study to Assess the Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Participants Who Are Assessed to be at Imminent Risk for SuicideNCT02133001 · 2014-05-23

A Study of the Efficacy of Intravenous Esketamine in Adult Patients With Treatment-Resistant DepressionNCT01640080 · 2012-06-27

Common conditions

Leading sponsors

Janssen Research & Development, LLC7 Beijing Tiantan Hospital1 China Medical University, China1 Göteborg University1 Janssen-Cilag Ltd.1 Mark Niciu1 Massachusetts General Hospital1 Medical University of Vienna1 Peking University First Hospital1 The Royal's Institute of Mental Health Research1 University of Sao Paulo1 University of Zagreb1 VA Office of Research and Development1 Yangzhou University1

Trial status mix

COMPLETED11

RECRUITING5

UNKNOWN2

TERMINATED1

WITHDRAWN1

Phase mix

PHASE25

PHASE45

PHASE34

NA3

PHASE12

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.